FMP

FMP

Enter

MTNB - Matinas BioPhar...

photo-url-https://images.financialmodelingprep.com/symbol/MTNB.png

Matinas BioPharma Holdings, Inc.

MTNB

AMEX

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

0.6 USD

-0.0105 (-1.75%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Mr. Jerome D. Jabbour J.D.

sector

Healthcare

industry

Biotechnology

exchange

AMEX

Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the preventio...

CIK

0001582554

ISIN

US5768101058

CUSIP

576810105

Address

1545 Route 206 South

Phone

908 484 8805

Country

US

Employee

32

IPO Date

Jul 21, 2014

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

MTNB Financial Summary

CIK

0001582554

Exchange

AMEX

Industry

Biotechnology

Sector

Healthcare

CUSIP

576810105

ISIN

US5768101058

Country

US

Price

0.6

Beta

1.73

Volume Avg.

213.1k

Market Cap

3.05M

Shares

-

52-Week

0.5-21.5

DCF

-0.09

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.13

P/B

-

Website

https://www.matinasbiopharma.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest MTNB News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep